Journal article
Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function
Robyn H Guymer, Kate H Brassington, Peter Dimitrov, Galina Makeyeva, Malcolm Plunkett, Wie Xia, Devinder Chauhan, Algis Vingrys, Chi D Luu
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | WILEY-BLACKWELL | Published : 2014
DOI: 10.1111/ceo.12247
Abstract
BACKGROUND: A novel, ultra-low energy nanosecond laser (retinal rejuvenation therapy) has been developed with the aim to slow progression of early age-related macular degeneration (AMD). The safety, changes in fundus characteristics and macular function in a cohort of participants with bilateral intermediate AMD are reported. DESIGN: Prospective non-randomised, pilot intervention study. PARTICIPANTS OR SAMPLES: Subjects with bilateral intermediate AMD (n = 50, aged 50-75 years). METHODS: Ultra-low energy laser pulses applied in 12 spots around the macula of one eye (0.15-0.45 mJ), using 400 μm diameter spot, 3 nanosecond pulse length, 532 nm wavelength and energy titrated to each patient. MA..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC Centre for Clinical Research Excellence
Funding Acknowledgements
This work was supported by a grant to the Centre for Eye Research Australia, from the Victorian State Government under the Victoria's Science Agenda Investment Fund and from Ellex R&D Pty Ltd, Adelaide. RHG receives a National Health and Medical Research Council (NHMRC) practitioner fellowship (#529905). CERA is supported by a NHMRC Centre for Clinical Research Excellence #529923 award and receives operational infrastructure from the Victorian Government. The funding organizations had no role in the design or conduct of this research.